Hiroko Koyama, Hiroshi Ikenuma, Hiroshi Toda, Goro Kondo, Masaki Hirano, Masaya Kato, Junichiro Abe, Takashi Yamada, Toshihiko Wakabayashi, Kengo Ito, Atsushi Natsume, Masaaki Suzuki
Journal: Bioorganic & medicinal chemistry letters 2017;27(9):1892-1896
PMID: 28363750
O-Benzylguanine (O-BG) is a substrate of O-methylguanine-DNA methyltransferase (MGMT), which is involved in drug resistance of chemotherapy in the majority of glioblastoma multiform. For clinical diagnosis, it is hoped that the MGMT expression level could be determined by a noninvasive method to understand the detailed biological properties of MGMT-specific tumors. We synthesized C-labeled O-[(3-methyl)benzyl]guanine ([C]mMeBG) as a positron emission tomography probe. Thus, a mixed amine-protected stannyl precursor, N-(tert-butoxycarbonyl)-O-[3-(tributylstannyl)benzyl]-N-(trifluoroacetyl)guanine, was subjected to rapid C-[C]methylation under [C]CHI/[Pd(dba)]/P(o-CHCH)/CuCl/KCO in NMP, followed by quick deprotection with LiOH/HO, giving [C]mMeBG with total radioactivity of 1.34GBq and ≥99% radiochemical and chemical purities.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Full Text Sources:
Medical:
Other Literature Sources:
Research Materials:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.